Alvotech (NASDAQ:ALVO) Q4 2023 Earnings Conference Call March 21, 2024 8:00 AM ET
Company Participants
Benedikt Stefansson - Senior Director of Investor Relations & Global Communications
Robert Wessman - Chairman & Chief Executive Officer
Anil Okay - Chief Commercial Officer
Joel Morales - Chief Financial Officer
Ming Li - Chief Strategy Officer
Conference Call Participants
Balaji Prasad - Barclays
Carl Byrnes - Northland Capital Markets
Kirsty Ross Stewart - Citi
Thibault Boutherin - Morgan Stanley
Patrik Ling - DNB Markets
Niall Alexander - Deutsche Bank
Operator
Good day and thank you for standing by. Welcome to the Alvotech Q4 and Full Year 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Benedikt Stefansson. Please go ahead.
Benedikt Stefansson
Thank you and good morning or afternoon to everyone joining this call today. Yesterday evening, the company issued a press release that can be found in the News section of our investor portal, investors.alvotech.com. The release outlines key highlights related to our full year 2023 results. Additionally, we will, throughout today's call, refer to a slide presentation which is available on our investor website in the Events section. If you have not already accessed the slides, please go to investors.alvotech.com and select Events.
Our presentation materials and some of our statements that we make today may include forward-looking statements. These statements do not ensure future performance and are subject to risks and uncertainties that are outlined in company filings with the Securities and Exchange Commission and the NASDAQ Iceland Stock Exchange. These risks and uncertainties could cause actual results to differ materially from forward-looking statements that we make.
With me on today's call are Robert Wessman, Chairman and CEO of Alvotech; Anil Okay, Chief Commercial Officer; Joel Morales, Chief Financial Officer; and Ming Li, Chief Strategy Officer.
With that, I would like to turn the call over to Robert Wessman, Founder, Chairman and CEO of Alvotech.
Robert Wessman
Thank you, Benedikt. And thank you all for joining us on today's earnings call and business update for the full year 2023. We are very excited about the position that we find ourselves in today. Alvotech has successfully cleared our inspection status with the U.S. FDA. This puts Alvotech in a position to access the largest pharma market in the world. This result has led to approval of SIMLANDI in U.S. and also clears the way for our biosimilar to STELARA which we expect will be approved by FDA next month.